AcelRx Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AcelRx Pharmaceuticals generated cash of -$17,492,000, which is more than the previous year. Cash used in financing activities reached the amount of $3,466,000 last year. Net change in cash is therefore -$14,554,000.
Cash Flow
| 2014 | -34.45M | -5.77M | 11.86M |
|---|---|---|---|
| 2015 | -19.95M | 8.20M | 59.63M |
| 2016 | -29.39M | 1.80M | -26K |
| 2017 | -29.76M | -9.97M | 12.32M |
| 2018 | -29.07M | -10.87M | 75.02M |
| 2019 | -51.18M | -36.56M | 14.45M |
| 2020 | -38.50M | 34.13M | 16.95M |
| 2021 | -30.00M | -26.12M | 41.51M |
| 2022 | -28.33M | 36.45M | -507K |
| 2023 | -17.49M | -528K | 3.46M |
ACRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 20.27M | 12.66M | 27.27M | 14.68M | 87.97M | 53.08M | 80.31M | 107.92M | 60.03M | 88.40M |
Operating activities | ||||||||||
Net income | -18.39M | 47.75M | -35.09M | -40.37M | -53.24M | -47.14M | -51.50M | -43.15M | -24.39M | -33.35M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 311K | 1.64M | 1.97M | 1.85M | 1.66M | 575K | 1.74M | 2.05M | 1.98M | 866K |
Stock-based compensation expense | 1.72M | 2.88M | 4.60M | 4.42M | 5.05M | 5.16M | 4.29M | 4.47M | 5.01M | 4.44M |
| Deferred income tax benefit | 1.72M | 2.88M | 4.60M | 4.42M | 5.05M | 5.16M | 4.29M | 4.47M | 5.01M | 4.44M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -189K | -149K | 475K | -203K | -383K | 1.48M | 4.3M | -2.54M | -3.28M | 90K |
Inventories | 61K | -107K | -295K | 957K | -3.39M | 102K | 920K | -1.68M | -466K | -79K |
Accounts payable | -575K | 551K | 111K | 1.01M | -19K | 458K | 309K | -437K | -786K | 90K |
Cash generated by operating activities | -17.49M | -28.33M | -30.00M | -38.50M | -51.18M | -29.07M | -29.76M | -29.39M | -19.95M | -34.45M |
Investing activities | ||||||||||
Purchases Of Investments | -3.65M | -7.86M | -70.45M | -44.61M | -100.06M | -30.55M | -7.56M | -996K | -7.26M | -17.43M |
Investments In Property Plant And Equipment | -100K | -364K | -1.82M | -1.85M | -3.47M | -819K | -2.40M | -3.72M | -1.45M | -5.50M |
Acquisitions Net | 0 | -1.68M | 0 | -35.99M | 33.09M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -528K | 36.45M | -26.12M | 34.13M | -36.56M | -10.87M | -9.97M | 1.80M | 8.20M | -5.77M |
Financing activities | ||||||||||
Common Stock Issued | 8.85M | 7.98M | 44.71M | 21.33M | 1.23M | 81.52M | 15.69M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -315K | -249K | -86K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -8.83M | -4.66M | 0 | -7.71M | 0 | 0 | 0 | 0 |
Cash used in financing activities | 3.46M | -507K | 41.51M | 16.95M | 14.45M | 75.02M | 12.32M | -26K | 59.63M | 11.86M |
Net Change In Cash | -14.55M | 7.61M | -14.61M | 12.59M | -73.29M | 35.07M | -27.40M | -27.61M | 47.88M | -28.36M |
Cash at end of period | 5.72M | 20.27M | 12.66M | 27.27M | 14.68M | 88.15M | 52.90M | 80.31M | 107.92M | 60.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |